Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial
Shanghai Jiao Tong University · Ruijin Hospital · +14 more institutions
Indexed incrossrefpubmed
Abstract
Objective
To assess the efficacy and safety of hydroxychloroquine plus standard of care compared with standard of care alone in adults with coronavirus disease 2019 (covid-19).
Design
Multicentre, open label, randomised controlled trial.
Citation impact
1,056
total citations
- FWCI
- 26.33
- Percentile
- 100%
- References
- 19
Citations per year
Authors
24Topics & keywords
Topics
Keywords
- Hydroxychloroquine
- Medicine
- Adverse effect
- Internal medicine
- Population
- Coronavirus disease 2019 (COVID-19)
- Disease
- Infectious disease (medical specialty)
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- SKShanghai Key Discipline for Respiratory DiseasesAward: 2017ZZ02014
- NNNational Natural Science Foundation of ChinaAwards: 2017ZX10202202-005-004, shslczdzk01103, 81770025, 2017ZX10202202, 2017ZZ02014, 81970020, 2017ZX10203201-008
- SJShanghai Jiao Tong University
- RHRuijin Hospital
- SOSchool of Medicine, Shanghai Jiao Tong University
- NKNational Key Research and Development Program of ChinaAwards: 2016YFC0901104, 2020YFC0844500